← Back to Search

Normally Sighted for Retinitis Pigmentosa

N/A
Waitlist Available
Research Sponsored by Nanoscope Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

Eligible Conditions
  • Retinitis Pigmentosa
  • Retinal Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MLSDT scores in normal and severely visually impaired subjects with a clinical diagnosis of RP on MLSDT
MLYMT scores in normal and severely visually impaired subjects with a clinical diagnosis of RP on MLYMT
Reliability and construct validity of MLSDT
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Severely Sight ImpairedExperimental Treatment1 Intervention
Participants with BCVA no better than logMAR 1.6 in better seeing eye, and worse than logMAR 1.9 in the worse seeing eye, and a clinical diagnosis of advanced RP
Group II: Normally SightedExperimental Treatment1 Intervention
Participants with clinically normal ocular findings and BCVA better than logMAR 0.3 in each eye.

Find a Location

Who is running the clinical trial?

Nanoscope Therapeutics Inc.Lead Sponsor
6 Previous Clinical Trials
79 Total Patients Enrolled
4 Trials studying Retinitis Pigmentosa
67 Patients Enrolled for Retinitis Pigmentosa
Aaron OsborneStudy ChairNanoscope Therapeutics Inc.
Dr Samarendra MohantyStudy ChairNanoscope Therapeutics Inc.
2 Previous Clinical Trials
33 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
27 Patients Enrolled for Retinitis Pigmentosa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
2023. "Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05820100.
All > Fargo
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top